Vemurafenib Production Cost Reports

The report provides a detailed analysis essential for establishing a Vemurafenib production plant. It encompasses all critical aspects necessary for Vemurafenib production, including the cost of Vemurafenib production, Vemurafenib plant cost, Vemurafenib production costs, and the overall Vemurafenib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Vemurafenib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Vemurafenib is a targeted oral inhibitor that is used for treating unresectable or metastatic melanoma. It stops the unusual signalling pathway to halt tumour cell proliferation and extend progression-free and overall survival compared to standard chemotherapy. It also holds orphan drug status for Erdheim-Chester disease (ECD), inducing durable responses in multisystem involvement, including bone, cardiovascular, and CNS manifestations. It is administered at 960 mg twice daily continuously until progression or intolerance and requires proper monitoring for class-specific adverse events like cutaneous squamous cell carcinomas (cuSCCs), photosensitivity, rash, new melanomas, QT prolongation, hepatotoxicity, arthralgias, and uveitis.

The market for Vemurafenib is influenced by growing cases of melanoma. The rising skin cancer rates from UV exposure, ageing demographics, and expanding precision oncology adoption contribute to its market growth. The advancements in combination therapies (like cobimetinib or immunotherapy) and regulatory approvals for Erdheim-Chester disease expand its applications.

The industrial Vemurafenib procurement is affected by high pricing and API supply volatility, influenced by a few manufacturers (Roche, Hetero, Shanghai Shenyue). Other factors like GMP demands, geopolitical trade factors, and post-marketing examination for toxicities like cuSCCs or QT prolongation add to its sourcing costs.

Raw Material for Vemurafenib Production

According to the Vemurafenib production plant project report, the key raw materials used in the production of Vemurafenib include 2,6-Difluoro-3-Nitrobenzaldehyde, 5-Bromo-1H-Pyrrolo[2,3-b]Pyridine, and 4-Chlorophenylboronic Acid.

Production Process of Vemurafenib

The extensive Vemurafenib production cost report consists of the following major industrial production process:

1. From 2,6-Difluoro-3-Nitrobenzaldehyde: The production process of Vemurafenib involves a convergent route. First, 2,6-difluoro-3-nitrobenzaldehyde is protected as an acetal, followed by nitro reduction to amine, and coupling with 5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl chloride (from Suzuki coupling of 5-bromo-1H-pyrrolo[2,3-b]pyridine and 4-chlorophenylboronic acid), and acetal deprotection. The process uses non-alcoholic solvents to avoid methoxy impurities, which leads to the formation of Vemurafenib.

Vemurafenib has the molecular formula of C23H18ClF2N3O3S and molecular weight of 489.92 g/mol. It is a solid kinase inhibitor that has a pyrrolopyridine core substituted by a p-chlorophenyl group and a 3-amino-2,6-difluorobenzoyl sulfonamide. It shows high lipophilicity with logP of 4.95-5.1, pKa of 8.87, and polar surface area of 91.92 Ų. It has 2 hydrogen bond donors, 4 acceptors, and 6 rotatable bonds. It has a melting point of 272 degree Celsius with low water solubility. It has high plasma protein binding over 99%, and moderate Caco-2 permeability of 2.9 × 10^-6 cm/s, which supports its oral bioavailability in oncology applications.